<DOC>
	<DOCNO>NCT00834275</DOCNO>
	<brief_summary>The objective study compare relative bioavailability cefadroxil 500 mg capsule ( manufacture Teva Pharmaceuticals USA ) DURICEF® 500 mg capsule ( manufacture Bristol-Myers Squibb Company ) dose ( 1 x 500 mg capsule ) normal healthy non-smoking male female subject fast condition .</brief_summary>
	<brief_title>Cefadroxil 500 mg Capsules Under Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Cefadroxil</mesh_term>
	<criteria>Nonsmoking male female minimum age 18 year ( i.e . nonsmoker nontobacco user least 90 day prior prestudy medical screening . Body mass index ( BMI= weight/height2 great equal 19kg/m2 less equal 30kg/m2 . Availability subject entire study period willingness adhere protocol requirement , evidence sign Informed Consent Form . Normal finding physical examination , 12lead ECG vital sign ( blood pressure 100140/6090 mmHg , heart rate 5099 beats/min , temperature 35.8°C 37.5°C . Negative drug abuse nicotine , hepatitis Bsurface antigen , hepatitis C HIV , female subject , pregnancy ( serum βCG ) . No clinical laboratory value outside acceptable range define BCR , unless Principal Investigator decide clinically significant . Female subject surgically sterile least six month postmenopausal least one year , avoid pregnancy prior study , study one month end study . Known history hypersensitivity cefadroxil ( e.g . Duricel® ) and/or relate drug family cephalosporin ( Cephalexin , Cefaclor , Cefazolin , Cefuroxime Axetil , Cefotetan , Cefprozil , Cefixime , Ceftriaxone ) , and/or penicillin ( Amoxicillin , Ampicillin , Clozacillin ) . Known history presence fod allergy , condition know interfere absorption , distribution , metabolism excretion drug . Any clinically significant illness last four week prior entry study . Presence andy significant physical organ abnormality . Any subject history drug abuse . Any history evidence psychiatric psychological disease ( include depression ) unless deem clinically significant Principal Investigator , medical designate . Use prescription medication within 14 day precede entry study . Use overthecounter ( OTC ) medication within 14 day precede entry study ( except spermicidal/barrier contraceptive product ) . Female subject : use contraceptive ( oral , transdermal , implant , Mirena® IUD ) within 30 day prior drug administration depot injection progestogen drug ( e.g . DepoProvera® ) within one year prior drug administration . Female subject : presence pregnancy lactation . Any subject blood drawn within 56 day precede study , conduct clinical study facility BCR , within lockout period specify previous study conduct BCR . Participation clinical trial investigational drug within 30 day precede study . Any subject donate blood within 56 day precede study . Any subject participate plasma donor plasmapheresis program within seven day precede study . Significant recent history asthma ( 12 year age ) . Any subject recent ( less one year ) history alcohol abuse . Known personal history gastrointestinal illness disease , particularly colitis . Any history severe allergic reaction ( include drug , food , insect bite , environmental allergen ) . Intolerance venipuncture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>